Aardvark Therapeutics, Inc. (AARD) company profile
Close on Nov 17, 2026Market cap $25.17MP/E –Yield –
About Aardvark Therapeutics
Pharmaceutical Preparations, SIC 2834
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic conditions. The company primarily targets bitter taste receptors expressed in the gut lumen to stimulate the release of endogenous signaling molecules that help alleviate hunger. Its product candidates include ARD-101, an oral gut-restricted agonist under evaluation for hyperphagia associated with Prader-Willi Syndrome, and ARD-201, a combination therapy intended for obesity and weight regain prevention.
The company operates in the United States and has conducted clinical trial activities across several international jurisdictions, including Australia, the United Kingdom, South Korea, and Canada. Aardvark Therapeutics maintains its principal executive offices in San Diego, California. The company relies on third parties and clinical sites to support the ongoing development and evaluation of its investigational product candidates across these geographic regions.
Summary of the business section of Aardvark Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aardvark Therapeutics, Inc.
- Founded
- 2017
- Headquarters
- San Diego, CA
- Address
- 4370 La Jolla Village Drive, Suite 1050 92122
- Phone
- (858) 225-7696
- Website
- aardvarktherapeutics.com
- Employees
- 40, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, San Diego, California
Stock & identifiers
- Ticker
- AARD
- Exchange
- Nasdaq
- IPO date
- Feb 13, 2025
- Shares outstanding
- 22M, Jul 31, 2026
- Public float
- $162.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1774857
- CUSIP
- 002942100
- ISIN
- US0029421007
- FIGI
- BBG01223DLB2
- Share class FIGI
- BBG01223DLC1
- EIN
- 82-1606367
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tien-Li Lee | Chief Executive Officer, Director | 3,025,641 |
| Manasi Jaiman | Chief Medical Officer | – |
| Nelson Sun | See Remarks | 35,475 |
| Bryan Jones | Chief Operating Officer | 1,250 |
| Zhongwei Zhang | Director | – |
| Jeffrey Chi | Director | 133,364 |
| Susan E. Graf | Director | – |
| Roy D. Baynes | Director | – |
| Victor Edward Tong Jr | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| Tien-Li Lee, M.D. Chief Executive Officer | $630.79K | $5.09M | $342.87K | $6.07M | +569% |
| Nelson Sun Chief Financial Officer and Chief Operating Officer | $432.65K | $1.94M | $170.65K | $2.55M | – |
| Manasi Jaiman, M.D., M.P.H. Chief Medical Officer | $495.96K | $1.18M | $197.08K | $1.87M | +130% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 13, 2025
- Offer price
- $16.00
- Securities offered
- 5,888,000
- Gross proceeds
- $94.21M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Aug 12, 2025
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 40 employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 13, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 10, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?